January 16, 2020

New partnership with Thermo Fisher Scientific to build Civica’s internal pipeline of medications for use in emergency and critical care in the U.S.

Media Coverage

Civica Rx Partners with Thermo Fisher Scientific to Develop and Manufacture Drugs with a History of Drug Shortages
Civica Advances Drug Supply Strategy with Thermo Fisher Deal
Civica Rx Inks Deal to Create Its Own Drugs
Focus on
9

critical medications

January 23, 2020

Partnership with BCBS to bring lower cost Civica medicines to consumers through outpatient pharmacies

Civica and 18 Blue Cross Blue Shield plans announced an initiative to lower the cost of drugs for consumers. The effort, which focuses on a targeted list of generic drugs in the retail setting, provides opportunities for additional health plans, states, employers and pharmacies to join.

Media Coverage

Blue Cross and Blue Shield Companies Join Forces with Civica Rx to Lower Costs of Select High-Cost Generic Medications
Major Insurers Pledge $55 Million to Try to Lower Generic Drug Prices
Civica Rx Teams with Blue Cross Blue Shield to Widen Its Alternative Market for Generics

March through April 2020

Civica begins providing discounted essential medications to 340B eligible hospitals to help serve high needs populations

Under Section 340B of the Public Health Service Act, pharmaceutical manufacturers participating in Medicaid also provide discounts on the prices of outpatient drugs to healthcare organizations that care for many uninsured and low-income patients.

These include public and nonprofit disproportionate share hospitals that serve low-income and indigent populations, community health centers, children’s hospitals, hemophilia treatment centers, critical access hospitals, sole community hospitals and rural referral centers.

March through April 2020

Civica is named one of the 10 Most Innovative Not-for-profit Organizations of 2020

…for manufacturing generic drugs at lower prices to combat shortages and rising healthcare costs

“The news is filled with healthcare stories about people unable to afford their insulin, or companies driving up the cost of needed interventions like EpiPens. Civica Rx is a not-for-profit drug company designed to combat these horror stories, by creating stable supplies of generic drugs, to prevent them from having sudden price spikes. The company delivered its first drug, the antibiotic Vancomycin, this year.”

Fast Company, March 10, 2020

Media Coverage

The 10 Most Innovative Not-for-profit Organizations of 2020
50+

Hospital Systems

1,200+

Hospitals

30%+

of hospital beds
(215K licensed beds)

$190

Million in capital

May 2020

Meeting surge demands for COVID-19 patient care

“Hospitals created their own drug maker just in time for pandemic”

11 Civica medications used in clinical protocols to treat COVID-19 patients include broad spectrum antibiotics, pain management medications, neuromuscular blocking agents and medications needed to treat co-morbidities

Media Coverage

Hospitals Created Their Own Drug Maker Just in Time for Pandemic
How Civica Rx Has Responded to Drug Shortages Caused by COVID-19
“WITHOUT THE READY SUPPLY OF CRITICAL MEDICATIONS FROM CIVICA, CRUCIAL THERAPIES FOR OUR PATIENTS COULD HAVE BEEN COMPROMISED DURING THE WORST POSSIBLE TIME AT THE EPICENTER OF THE PANDEMIC.”
Mark Pollard,
Vice President of Professional Services, NYU Langone Health

May 19, 2020

Civica Rx partners with Phlow Corporation on near-term COVID-19 response and future “end-to-end” U.S.-based generic drug manufacturing

Announces plans to build a new Civica sterile injectable drug manufacturing facility

Media Coverage

Civica Rx Partners on COVID-19 Response and “End-to-End” US Based Generic Drug Manufacturing
How Civica Helped Under-the-radar Phlow Nab a $354M COVID-19 Manufacturing Deal
Civica Rx Partners with US Government to Produce Generics for COVID-19 Response

May through June 2020

Civica provides 2.1 million vials of essential medicines for COVID-19 patients to the U.S. Strategic National Stockpile

Media Coverage

Bringing Drug Production Back to the US

June 2, 2020

Civica CEO Martin VanTrieste testifies before Congress on the security of the U.S. medicine supply chain

“The global coronavirus pandemic has highlighted weaknesses in the U.S. supply chain for essential medicines and other medical supplies…Many of the medicines used to manage COVID-19, including the sedatives and neuromuscular blocking agents essential for patients on ventilators, were already in short supply prior to the pandemic…Facing low margins and uncertain sales, companies are discouraged from investing in quality and incentivized to move production out of the U.S. to economies with lower labor costs, lower regulatory compliance costs and where they may receive direct or indirect support from foreign governments to build new facilities.”

Martin VanTrieste,
CEO, Civica Rx

Media Coverage

Civica CEO’s Congressional Testimony on Generic Drug Supply
COVID-19 and Beyond: Oversight of the FDA’s Foreign Drug Manufacturing Inspection Process

June 18, 2020

Kaiser Permanente joins Civica to help secure supplies of essential generic medications during COVID-19 and beyond

Civica’s Governing board welcomes Kaiser

Media Coverage

Kaiser Permanente Joins Forces with Civica Rx to Improve Availability and Affordability of Essential Generic Medications
Kaiser Permanente Adds Clout To Nonprofit Generic Drug Maker

July 7, 2020

Sandoz partnership formed to reliably supply medicines for optimal patient care in acute care settings

Medications: Antibiotics, acid reducers, blood thinners, blood pressure regulators and medicines required in the operating room

Media Coverage

Sandoz Collaborates with Civica Rx to Help Reduce Critical Generic Medicine Shortages in US Hospitals
Sandoz, Civica Rx Partner to Reduce Medicine Shortages in US Hospitals

September 6, 2020

Celebrating Civica’s 2nd Anniversary

From concept to today, Civica Rx (Civica, Inc) has proven to be a viable industry player, ensuring stable and predictable supplies of over 20 essential generic drugs so far, with an additional 20 under contract, and generating millions of dollars in savings for hospitals

Drug shortages can cause clinical and financial distress for patients and their families – medication errors, adverse events and increased out of pocket costs. For hospitals, drug shortages lead to increased costs due to price spikes and the need for more experts to manage shortages and search for the best possible alternative treatments.

As of September 2020, and one year after the first patient was treated with a Civica medication in Utah, Civica has delivered over eleven million vials and syringes to hospitals, treating up to 3 million patients across the United States.

In addition to stabilizing the supply of essential generic medicines, the collaborative Civica model has already saved health systems millions of dollars, with more savings to come.

11
Million Vials
Up to
3
Million Patients
48
Civica Employees
40
Civica essential medications under contract, building towards 100 by 2023
10
Manufacturing Partners
(Xellia, Hikma, Exela, Sandoz, Dash, BioE, American Regent, Thermo Fisher Scientific and two others to be announced in the future)